Statins associated with improved mortality among patients with certain histological subtypes of lung cancer

Lung cancer is the deadliest cancer in the United States, with only 18% of patients surviving longer than 5 years after diagnosis. As a result, extensive clinical investigations are currently under way to identify novel drug candidates that can improve the prognosis of lung cancer patients. In recent years, a class of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors called statins have garnered widespread attention for their possible therapeutic activity in several cancer types, including lung cancer [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research